



World Society of Intra Venous Anaesthesia Onlus

2nd World Congress of TOTAL INTRAVENOUS ANAESTHESIA - TCI

Berlin, Germany | April 23 - 25, 2009




BERLIN 2009




www.kenes.com/tiva-tci

Final Program



Rome is where the heart is.



Recruiting healthcare professionals into permanent roles is our specialty, and what we do best. Our unique approach to healthcare recruitment allows us to help doctors from all around the world to find new positions all around the globe.

Rome, Italy

We currently have positions for anaesthetists in NHS trusts UK wide across all grades. If you are eligible for GMC Full Registration, or Specialist Registration, we would love to hear from you.

Plus, register with HCL International by **Sunday 10th May** and you will go into the draw to win a trip for two to Rome.

To register, email us your CV, or call one of our consultants.

HCL
International
Global Healthcare Recruitment

+44 207 861 8950
doctors@hcl-international.co.uk
www.hcl-international.co.uk



2nd World Congress of
TOTAL INTRAVENOUS
ANAESTHESIA – TCI
Berlin, Germany | April 23 – 25, 2009



Final Program

Congress Organizers

KENES *International*

CARES FOR YOUR ORGANIZATION
GLOBAL CONGRESS ORGANIZERS AND
ASSOCIATION MANAGEMENT SERVICES

c/o Kenes International -
Global Congress Organizers
and Association Management Services
17 Rue de Chantepoulet, P.O. Box 1726
CH-1211 Geneva 1, Switzerland
Tel: +41 22 908 0488, Fax: +41 22 906 91 40
E-mail: tivatci@kenes.com
Web: www.kenes.com/tiva-tci

TABLE OF CONTENTS

Welcoming Words III

Committees

World SIVA

About Berlin

Acknowledgements

CME Accreditation

General Information

List of Exhibitors

Exhibitors' and Sponsors' Profiles

Timetable

Scientific Program

Thursday, April 23, 2009

Friday, April 24, 2009

Saturday, April 25, 2009

Poster Session

Friday, April 24 – Saturday, April 25, 2009

Index of Authors

WELCOMING WORDS

Dear Colleague,

Over the past years, anaesthesiologists in most countries have developed a major interest in intravenous anaesthesia. This has been prompted in many cases by the availability of improved drugs, such as propofol and remifentanyl, and the more widespread introduction of target controlled infusion systems. These factors, together with improved education, have led to growing awareness of the value of these new techniques for routine anaesthesia and also to the rapidly evolving area of conscious sedation.

Following the 1st World Congress of Intravenous Anaesthesia, World SIVA has been established with the aim of coordinating and facilitating high quality and educational presentations in this emerging area of anaesthetic practice.

This Congress aims to promote the highest quality of education for those involved with all drugs administered intravenously, and assist the introduction of new techniques into the standard curricula and examination systems of individual countries.

We hope you find this to be an exciting and educational program, where you can meet others with similar interests, discuss problems with world experts in this area and enjoy the social aspects of the program.



Professor Quirino Piacivoli, MD
President, World SIVA



COMMITTEES

EXECUTIVE COMMITTEE OF WORLDSIVA

President

Quirino Piacevoli, Italy

Vice Presidents

Steven Shafer, USA

Thomas Schnider, Switzerland

Charles Minto, Australia

Secretary

Freddy Del Gaudio, Italy

Treasurer

Pedro Gambus, Spain



ABOUT WORLD SIVA

The World Society of Intravenous Anaesthesia is a scientific non-profit organisation devoted to improving the standard of intravenous anaesthesia and intravenous anaesthesia delivery systems, including target and feedback controlled infusion technology.

World SIVA promotes the clinical application of existing knowledge and the acquisition of new knowledge by bringing together clinicians, scientists and educators from around the world who practice, study and teach intravenous anaesthesia.

The aims of the World Society of Intravenous Anaesthesia are:

- to improve the standard of intravenous anaesthesia.
- to improve intravenous anaesthesia delivery systems, including target controlled infusion (TCI) technology.
- to promote the clinical application of existing and new knowledge in intravenous anaesthesia.
- to promote scientific education in intravenous anaesthesia.
- to bring together those who study and practice intravenous anaesthesia.
- to develop and recommend safety and quality standards for intravenous anaesthesia.
- to address any possible ethical problems associated with intravenous anaesthesia.
- to establish an international network for the exchange of information and expertise about intravenous anaesthesia.
- to provide and promote the information regarding opportunities for post graduate training and research in intravenous anaesthesia.
- to promote or sponsor publications or periodicals concerning intravenous anaesthesia.
- to arrange at regular intervals a World Congress in intravenous anaesthesia and to sponsor regional congresses and encourage meetings in this field.
- to affiliate with other national and international scientific organisations active in all aspects of intravenous anaesthesia.

**For more information and details on becoming a member,
please visit: www.worldsiva.org**

ABOUT BERLIN

Berlin is one of Europe's leading cosmopolitan centers, home to the German Parliament, the "Bundestag". Berlin is a city on the cutting edge, and has often been in the spotlight on the world stage over the past 100 years.

Berlin has always impressed visitors with its diversity of museums, palaces and historic edifices. Its historic significance as a former royal residence comes alive on almost every corner, especially in the eastern part of the city.



One of the most important historic monuments and infamous symbols of the city is the remains of the barrier built in 1961 which became known as the Berlin Wall. This wall divided the city into two parts - East and West. The Berlin Wall was dismantled in 1989, once again reuniting East and West Germany. Although the wall has come down, the differences between the utilitarian East and decadent West are still apparent.

Berlin is a mixture of both modern and ancient architecture that characterizes the cityscape.

ACKNOWLEDGEMENTS

We wish to express our gratitude to the following sponsors who, through their generosity, have helped to make this Congress possible:

Platinum Sponsors



Gold Sponsors



Silver Sponsors



Bronze Sponsors



Other Sponsors



Hospira Australia

GENERAL INFORMATION

DATE

April 23 – 25, 2009

LOCATION

Maritim Hotel Berlin
Stauffenbergstr. 26, 10785 Berlin, Germany
Tel: +49 (0) 30 2065-0, Fax +49 (0) 30 2065-1000

REGISTRATION/INFORMATION/SECRETARIAT/ ACCOMMODATION DESKS

Registration desks will be situated in the Grand Hall at the Maritim Hotel for the duration of the Congress.

OPENING HOURS

Thursday, April 23, 2009	11:00 – 20:00
Friday, April 24, 2009	07:30 – 19:30
Saturday, April 25, 2009	07:00 – 19:00

BADGE

Upon registering you will receive your Congress Kit in which you will find your name badge. You are kindly requested to wear your badge during all Congress sessions and events.

EXHIBITION OPENING HOURS

Thursday, April 23, 2009	17:00 – 21:00
Friday, April 24, 2009	10:00 – 17:00
Saturday, April 25, 2009	10:00 – 17:00

MAIL/MESSAGES/MEDICAL ASSISTANCE/LOST & FOUND

Please approach the registration desk.

LANGUAGE

The official language of the Congress is English.

SESSIONS

Please make sure to be in session halls on time as all sessions will begin as per the timetable.

SPEAKERS' READY ROOM - ORAL PRESENTATIONS

A Speaker's Ready Room will be available for speakers every day throughout the Congress. If using a PowerPoint (or any other computer) presentation, please note you need to bring it on a CD, DVD or on a "disk on key" (using the USB port in the computer)

and load it on one of the Congress' computers in the Speakers' Ready Room, with the assistance of the IT technicians there, at least 1 hour before the start of the session.

You may supply your own laptop computer as a back-up.

If combining **video films** with **PowerPoint**, please make sure to check it in the session hall where your lecture is taking place during a coffee or lunch break prior to your session, at least 30 minutes before the start of the session - in addition to checking it in the Speakers' Ready Room.

Please note that the Congress computers in the session halls are being supplied with Windows XP and Office 2003 (at least).

Important Note for Macintosh Users

If using a Macintosh laptop computer, please note that you need to supply your own, **confirm that it has a VGA socket** for external signal and come to check it first in the Speakers' Ready Room as soon as you arrive and later on in the session hall where your lecture is taking place during the coffee or lunch break prior to your session, at least 30 minutes before the start of the session.

Please note that VHS Video projection, 35 mm' slide projection and OH projection will not be available.

POSTERS

Posters are located in the gallery of the Exhibition Hall on the upper level. All posters will be on display on Friday, April 24 and Saturday, April 25.

POSTER PRESENTERS

Please see the scientific program for the board number on which you should display your poster.

The poster presentations are an important part of the Scientific program and an invaluable opportunity for the exchange of ideas and update on new research. The main opportunity for poster viewing and discussion is during the coffee breaks. Authors are requested to stand by their posters during the breaks on **Friday, April 24** and **Saturday, April 25** as follows:

Morning Coffee Breaks: Even Poster Board Numbers

Afternoon Coffee Breaks: Odd Poster Board Numbers

Posters are to be mounted from the start of sessions on Friday, April 24.

Please remove your poster at the conclusion of sessions on Saturday, April 25.

The Congress Organizers will not be responsible for posters that are not removed on time.

X **GENERAL INFORMATION (Cont.)**

LUNCH AND COFFEE BREAKS

Lunch and coffee breaks will be offered as per the breaks indicated in the timetable. Catering areas will be available in the Exhibition areas.

CME ACCREDITATION (EACCME)

The 2nd World Congress of Total Intravenous Anaesthesia – TCI is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialist (UEMS), www.uems.net.

The 2nd World Congress of Total Intravenous Anaesthesia – TCI is designated for a maximum of (or “for up to”) **14 hours** of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

EACCME credits are recognised by the American Medical Association towards the Physician’s Recognition Award (PRA). To convert EACCME credit to AMA PRA category 1 credit, contact the AMA.

CERTIFICATE OF ATTENDANCE

The Certificate of Attendance is included in your participants’ kit.

SMOKING POLICY

Smoking is prohibited at all times in the congress halls, exhibit halls and restrooms. Your compliance is appreciated.

MOBILE PHONES

Please note that mobile phones must be switched off during all sessions.

CONGRESS ORGANISERS AND SECRETARIAT

KENES *International*

CARES FOR YOUR ORGANIZATION

GLOBAL CONGRESS ORGANIZERS AND
ASSOCIATION MANAGEMENT SERVICES

1 – 3 Rue de Chatepoulet

PO Box 1726, CH-1211 Geneva 1, SWITZERLAND


Tel: +41 22 908 0488, Fax: +41 22 906 91 40

E-mail: tivatci@kenes.com

Website: www.kenes.com/tiva-tci

LIST OF EXHIBITORS

Company	Booth #
Arcomed AG	2
Aspect Medical Systems International B.V.	7
B. Braun Melsungen AG	12
BD	15
Cardinal Health International	9
Dräger Medical Deutschland GmbH	16
Fresenius Vial	1a
GE Healthcare Finland OY	1
GlaxoSmithKline GmbH & Co.KG	2A
Mediplus Limited	4
Med-Storm Innovation	18
Schering-Plough	11
Schreiner MediPharm	17
Wisepress Ltd	TBA
World SIVA	6



XII **EXHIBITORS' & SPONSORS' PROFILES**

Aspect Medical Systems International B.V.



Rijnzathe 7d2
3454 PV De Meern, The Netherlands
Website: www.aspectmedical.com, www.BISeducation.com

Aspect Medical Systems, Inc. manufactures and markets clinically proven brain monitoring technology that directly measures the patient-specific effects of anaesthetics and sedatives on the brain. Aspect's BIS™ (Bispectral Index™) technology enables medical professionals to better manage a patient's level of consciousness and facilitate quality and safety improvements in patient care.

B. Braun Melsungen AG



Carl-Braun-Strasse 1
D-34212 Melsungen, Germany
Website: www.bbraun.com

B. Braun, a globally operating family owned company with more than 35,000 employees, offers hospitals and practitioners all over the world a wide range of products and services. With a large network of subsidiaries in more than 50 countries in the world, the company has tradition and competence in fields such as Anesthesiology, Intensive Care Medicine, Cardiology and Surgery. B. Braun is leading supplier of Infusion Pumps and Fluid Management Workstations. More than 40 injectable drugs are sold worldwide by B. Braun, e. g. Propofol-®Lipuro in more than 90 countries.

BD



Tullastr. 8 - 12
Heidelberg, 69126, Germany
Website: www.bd.com

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in

combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

Cardinal Health International



A-One Business Centre
Zone d'activités Vers-la-Pièce n°10
CH-1180 Rolle
Switzerland
Website: www.cardinalhealth.com

Cardinal Health, Inc. (NYSE: CAH) is a global company serving the health-care industry with products and services that help hospitals, physician offices and pharmacies reduce costs, improve safety, productivity and profitability, and deliver better care to patients. With a focus on making supply chains more efficient, reducing hospital-acquired infections and breaking the cycle of harmful medication errors, Cardinal Health develops market-leading technologies, including Alaris® IV pumps, Pyxis® automated dispensing systems, VIASYS® Respiratory Care - Ventilation and Pulmonary Diagnostic Products as well as the NeuroCare products and the CareFusion™ patient identification system. More information about the company may be found at www.cardinalhealth.com.

Dräger



Website: www.draeger.com

Dräger is an international leader in the fields of medical and safety technology. Dräger products protect, support and save human life.

The current product range of the medical division includes anesthesia workstations, ventilators for emergency, critical and home care as well as warming therapy for premature infants. Patient monitoring, IT solutions, accessories and consumables, ceiling supply units, light systems and central supply systems for medical gases complete the portfolio.

For more information, visit www.draeger.com.

Fresenius Kabi Deutschland GmbH



Else-Kröner-Straße 1
61352 Bad Homburg
Germany
Website: www.fresenius-kabi.com

Fresenius Kabi is the leader in infusion therapy and clinical nutrition in Europe and in its most important countries of Latin America and Asia Pacific. For infusion therapy Fresenius Kabi offers products for fluid and blood volume replacement, intravenously administered drugs, infusion technologies, infusion disposables as well as medical devices for blood collection and processing. For clinical nutrition the company provides parenteral nutrition and enteral nutrition as well as nutrition pumps and infusion disposables. Fresenius Kabi is focused on the therapy and care of critically and chronically ill patients in and outside the hospital.

GE Healthcare



GE Healthcare

Kuortaneenkatu 2 / P.O. Box 900
00031 GE (Helsinki)
Finland
Website: www.gehealthcare.com

GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our expertise and broad range of products and services in medical imaging and information technologies, medical diagnostics, patient monitoring systems, performance improvement, drug discovery, and biopharmaceutical manufacturing technologies are helping clinicians around the world re-imagine new ways to predict, diagnose, inform and treat disease, so their patients can live their lives to the fullest. Headquartered in the United Kingdom, GE Healthcare is a US\$15 billion unit of General Electric Company. GE Healthcare employs 45,000 people committed to serving healthcare professionals in more than 100 countries.

GlaxoSmithKline GmbH & Co. KG



Theresienhöhe 11
80339 München
Germany
Website: www.gsk.com

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information, please visit our booth Nr 2 A in the exhibition or the World Wide Web at www.gsk.com

Mediplus Limited



Unit 7, The Gateway Centre
Coronation Road
Cressex Business Park
High Wycombe
Buckinghamshire HP12 3SU
United Kingdom
Website: www.mediplus.co.uk

Mediplus Limited is a privately owned company that began trading in 1986. It is a manufacturer of specialist medical disposables for the hospital market where its areas of interest are in urology, gastroenterology, anaesthetics and general surgery. The company's line of TIVA (Total Intravenous Anaesthesia) sets and multi-lumen peripheral connectors are one of the most comprehensive available on the market. These sets and connectors were developed with the help of anaesthetists working for the NHS and to whom safety and quality are a priority.



Med-Storm Innovation

Gimle terrace 4
No 0264 Oslo
Norway
Website: www.med-storm.com

Med-Storm Innovation (MSI) is a Norwegian medical technology company. MSI has developed the first commercial reliable product available for detecting pain in non communicating patients such as preterm infants, intensive care unit patients, patients in anaesthesia, and patients postoperatively. The device is a Skin Conductance Algesimeter which analyzes emotional sweating (skin conductance) for monitoring and detecting pain and awakening of patients. Functions both for Neonatal, ICU units and General Anaesthesia
CE marked and commercially available in Europe.
US 510K within 2009.

HCL International



Greener House
66-68 Haymarket, London
SW1Y 4RF
www.hcl-international.co.uk

Recruiting healthcare professionals into permanent roles is our specialty, and what we do best. As part of the UK's largest specialist healthcare recruitment company, we have helped thousands of healthcare professionals to find employment all around the world.

With clients spanning across the globe, including Sri Lanka, Nepal, Australia, America, South Korea, Canada, Philippines, UK, Europe and more; HCL International provide a truly global approach to healthcare recruitment.

We currently have permanent positions for Anaesthetist Doctors in NHS Trusts and private clinics UK wide across a broad range of grades. If you are eligible for GMC Full Registration, or Specialist Registration, we would love to hear from you .

Registrations made by your friends and colleagues in all other specialties as well, will also go in to the draw to win a trip for two to Rome.

Schering-Plough



2000 Galloping Hill Road
Kenilwroth, NJ, 07033
USA
Website: www.schering-plough.com

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, animal health and consumer health care products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.

Schreiner MediPharm



A division of Schreiner Group GmbH & Co. KG
Bruckmannring 22
85764 Oberschleissheim
Germany
Website: www.schreiner-medipharm.com

Schreiner MediPharm specializes in the requirements of the pharmaceutical industry. The company is a leader in the development and manufacture of customized, intelligent marking solutions with innovative, value-adding functions, e.g. labels with integrated hangers, labels with removable documentation parts as well as multi-page labels. Additionally, the product portfolio includes syringe labels with integrated needle protection as well as anti-tampering and counterfeiting protection solutions. Schreiner MediPharm is a certified A-level supplier to the leading global pharmaceutical corporations and complies with the high quality standards demanded by the pharmaceutical industry. The company is represented around the world, all the way to Japan.

Wisepress Online Bookshop

The Old Lamp Works
25 High Path
Merton Abbey
London SW19 2JL
United Kingdom
Website: www.wisepress.com

Wisepress.com, Europe's leading conference bookseller, has a complete range of books and journals relevant to the themes of the meeting. Books can be purchased at the stand or, if you would rather not carry them, posted to you – Wisepress will deliver worldwide. In addition to attending 250 conferences per year, Wisepress has a comprehensive medical and scientific bookshop online with great offers, some up to 40% off the publisher list prices.

World Siva

Please see pg V for further information.

Fast track approach – how to satisfy patients, doctors and hospitals

Symposium

April 24th, 16.30 – 18.30, workshop 4A, Hall E

Prof Q. Piacevoli,
Rome, Italy

Chairman's Introduction

**Dr P. Schjønsby/
RN S. Ødegård,**
Oslo, Norway

Enhanced recovery after surgery –
a new world for gynaecological
patients

Discussion

Dr. J. Ender,
Leipzig, Germany

Bypassing the ICU in cardiac surgery –
a new fast track concept

Discussion

If you are interested in more details,
or a face-to-face discussion, we will
be pleased to welcome you at the
GSK exhibition stand.

Ultiva[®]
Remifentanyl

gsk
GlaxoSmithKline

For Prescribing Information please see extra page in this program.

PRESCRIBING INFORMATION: Ultiva (remifentanil hydrochloride) for injection 1mg, 2mg, 5mg.

The following is for guidance only. **Refer to Summary of Product Characteristics (SmPC) before prescribing.** Ultiva is a very short acting opioid for injection/infusion.

Indications: General Anaesthesia. Analgesia/sedation in ICU. **Dosage:** tailor to individual. **Anaesthesia:** *Adults:* Dilute to e.g. 50mcg/ml (2mg in 40 ml). Induction (not sole agent): 1mcg/kg bolus administered over not less than 30 seconds then 0.5 – 1mcg/kg/min. Reduce to 0.25mcg/kg/min (using e.g. propofol or isoflurane). Maintenance: 0.05 – 2mcg/kg/min with 0.5 – 1mcg/kg bolus or alter infusion rate as needed. Due to rapid metabolism, no residual opioid activity will be present 5 - 10 minutes after discontinuation. Where post-operative pain anticipated, analgesics should be administered prior to discontinuation of Ultiva. **Spontaneous ventilation:** Respiratory depression likely; ventilatory support may be required. Avoid inadvertent administration of Ultiva remaining in IV lines and cannulae. **Elderly (over 65 years):** initiate half adult dose. **Children:** see SmPC. **Cardiac surgery:** See SmPC. **Intensive Care:** *Adults:* 0.1 to 0.15mcg/kg/min. Increase by 0.025mcg/kg/min. If inadequate sedation at 0.2mcg/kg/min add sedative. **Elderly (over 65 years):** No initial dose reduction required. **Children:** not recommended. **Renal/hepatic impairment:** No dosage adjustment necessary. Severe hepatic impairment may be slightly more sensitive to respiratory depressant effects. **Contraindications:** Epidural and intrathecal use. Known hypersensitivity to any ingredient or other fentanyl analogues. Not for use as sole induction agent. **Warnings and Precautions:** Administer only in appropriate setting. Administer into fast-flowing or via dedicated IV line and remove on discontinuation, to avoid inadvertent administration. Prior to discontinuation, administer analgesics where post-operative pain anticipated. Administer bolus doses over not less than 30 seconds. Debilitated, hypovolaemic, and elderly patients may be more sensitive to cardiovascular effects. May produce dependency. **Interactions:** As with other opioids, remifentanil decreases the requirements for inhaled and IV anaesthetics and benzodiazepines. Concomitant cardiac depressant drugs may exacerbate cardiovascular effects. **Pregnancy and lactation:** No adequate and well-controlled studies. Use only if potential benefit justifies potential risk to the foetus. Caution in nursing mothers. Insufficient evidence to recommend use during labour or Caesarean section. May cause respiratory depression in neonate. **Undesirable effects:** Acute respiratory depression, bradycardia, hypotension and/or skeletal muscle rigidity all resolve within minutes of discontinuation or decrease in the administration rate. Post-operative shivering, apnoea, hypertension, hypoxia, pruritus, constipation, aches, sedation, nausea and vomiting have also been reported. Very rarely, allergic reactions, including anaphylaxis, and bradycardia leading to asystole. As with other opioids remifentanil may produce dependency. **Basic NHS Costs:** Available as 1mg, 2mg and 5mg vials containing white/off-white powder for reconstitution to provide 1mg/ml remifentanil hydrochloride. 1mg vial x 5, £25.58, 2mg vial x 5, £51.15, 5mg vial x 5, £127.88. **Legal category:** CD POM. **Product Licence numbers:** Ultiva 1mg PL19494/0026, Ultiva 2mg PL19494/0027, Ultiva 5mg PL19494/0028. **Marketing Authorisation holder:** GlaxoSmithKline UK Ltd, 980 Great West Road, Brentford, Middlesex TW8 9GS. Prescribing Information updated: July 2008ULT/PRI/08/29184/2

Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.gov.uk. Adverse events should also be reported to **GlaxoSmithKline on 0800 221 441.**

Ultiva[®]
Remifentanil

 GlaxoSmithKline



2nd World Congress of
TOTAL INTRAVENOUS
ANAESTHESIA - TCI



SCIENTIFIC PROGRAM

Thursday, April 23



TCI and TIVA in Clinical Practice

B. Braun Symposium,
SIVA – 2nd World Congress of
TOTAL INTRAVENOUS ANAESTHESIA – TCI,
Berlin, Maritim Hotel,
Saturday, April 25th, 2009 08:30 a.m. – 10:00 a.m.

- TIVA in Children
- TCI and Change of Drug Concentration
- TCI in Short-term Sedation

Chair: P. A. Lönnqvist, Stockholm, Sweden



B | BRAUN
SHARING EXPERTISE



SCIENTIFIC PROGRAM

Friday, April 24



See the difference in anaesthesia

Fresenius Kabi is the expert in anaesthesia that covers all your needs - from the drug to the vein.

Our offer spans anaesthetic drugs, infusion pumps for TIVA and TCI as well as disposable application devices.

See the difference in anaesthesia on our booth.



**FRESENIUS
KABI**

caring for life

www.fresenius-kabi.com



2nd World Congress of
TOTAL INTRAVENOUS
ANAESTHESIA - TCI



SCIENTIFIC PROGRAM

Saturday, April 25

Better Opiate Administration with TCI

Alaris® Products



TCI workshop

by;

Prof. Dr. M. Struys, MD, PhD
(Netherlands)

Dr. H. Vereecke, MD, PhD
(Belgium)

Venue:
2nd World Congress of
Total Anaesthesia TIVA TCI
Berlin, Germany

Date & Time:
Friday 24th April 2009
14.30 - 16.00



Registration: If you are registered to attend the 2nd World Congress of Total Anaesthesia TCI TIVA you may also attend this workshop but please be aware that places are limited.

If you would like more information about this workshop, please feel free to visit us in the main Hall Booth #9.



CardinalHealth

Essential to care™



POSTERS

Friday, April 24
to
Saturday, April 25



INDEX OF AUTHORS





Now, the *speed* to reverse any depth of blockade

Introducing BRIDION®: brings your patients back from any depth* of blockade—and fast¹

- **Unique BRIDION® molecule** encapsulates rocuronium or vecuronium, rendering them inactive¹
- **Rapidly reverses even deep** neuromuscular blockade in a matter of minutes^{1**}
 - 2.7 minutes from rocuronium-induced blockade
 - 3.3 minutes from vecuronium-induced blockade
- **Immediate reversal** available for the first time¹
 - 1.5 minutes when administered 3 minutes after 1.2 mg/kg of rocuronium
- **Minimal risk of side effects or residual blockade** when administered at recommended doses, with no need for concomitant anticholinergic agents^{1,2}

Bridion® 100 mg/ml Injektionslösung, Wirkstoff: Sugammadex

Zusammensetzung, Arznei-, wirks. Bestandt.: 1 ml enth. 100 mg Sugammadex. **Sonst. Bestandt.:** Salzsäure 3,7 % u./o. Natriumhydroxid (zur pH Einstellung), Wasser f. Inj.-zwecke.

Anwendungsgebiete, Aufhebung der durch Rocuronium o. Vecuronium induzierten neuromuskulären Blockade. Pädiatrische Pat.: Nur zur routinemäßigen Aufhebung einer Rocuronium-induzierten Blockade bei Kindern u. Jugendlichen empfohlen.

Gegenanzeigen. Überempfindl. geg. den Wirkstoff o. einen der sonst. Bestandt.

Vorsicht bei, schwer eingeschränkter Nieren-/Leberfunktion, verlängerter Kreislaufzeit, kontrollierter Natriumdiät.

Nebenwirkungen. Sehr häufig: Dysgeusie. Häufig: Narkosekomplikationen (Bewegung der Gliedmaßen o. des Körpers o. Husten während der Narkose/Operation, Grimassieren o. Saugen am Endotrachealtubus), Wiederauftreten einer Blockade. Gelegentlich: Wachheit während der Narkose/Operation, Bronchospasmen bei Pat. mit pulmonalen Komplikationen in der Vorgeschichte, allergische Reakt.

Verschreibungspflichtig, Weitere Angaben zur sicheren Anwendung d. Arzneimittels siehe Fachinformation, Stand d. Information: Juli 2008. Pharmazeutischer Unternehmer: N.V. Organon, Kloosterstraat 6, 5349 AB Oss, Niederlande.

*Moderate (reappearance of second twitch [T₂]) or deep (1-2 posttetanic counts [PTCs]) neuromuscular blockade¹

**In children: routine reversal of rocuronium-induced blockade.

References: 1. BRIDION® [summary of product characteristics]. Oss, the Netherlands: N.V. Organon; 2008. 2. Bom A, Bradley M, Cameron K, et al. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by cyclodextrin-based synthetic host. *Angew Chem.* 2002;114(2):275-280.

BRIDION.com

NEW
bridion®
sugammadex

 EssexPharma

Reversal just got rapid.



Now, the *speed* to reverse any depth of blockade

Introducing BRIDION®: brings your patients back from any depth* of blockade—and fast¹

- » **Unique BRIDION® molecule** encapsulates rocuronium or vecuronium, rendering them inactive¹
- » **Rapidly reverses even deep** neuromuscular blockade in a matter of minutes^{1**}
 - 2.7 minutes from rocuronium-induced blockade
 - 3.3 minutes from vecuronium-induced blockade
- » **Immediate reversal** available for the first time¹
 - 1.5 minutes when administered 3 minutes after 1.2 mg/kg of rocuronium
- » **Minimal risk of side effects or residual blockade** when administered at recommended doses, with no need for concomitant anticholinergic agents^{1,2}

Bridion® 100 mg/ml Injektionslösung, Wirkstoff: Sugammadex

Zusammensetzung, Arznei_lirks_Bestandt.: 1 ml enth. 100 mg Sugammadex. **Sonst_Bestandt.:** Salzsäure 3,7 % u./o. Natriumhydroxid (zur pH Einstellung), Wasser f. Inj.-zwecke.

Anwendungsgebiete, Aufhebung der durch Rocuronium o. Vecuronium induzierten neuromuskulären Blockade. Pädiatrische Pat.: Nur zur routinemäßigen Aufhebung einer Rocuronium-Induzierten Blockade bei Kindern u. Jugendlichen empfohlen.

Gegenanzeigen, Überempfindl. geg. den Wirkstoff o. einen der sonst. Bestandt.

Vorsicht bei, schwer eingeschränkter Nieren-/Leberfunktion, verlängerter Kreislaufzeit, kontrollierter Natriumdiät.

Nebenwirkungen, Sehr häufig: Dysgeusie, Häufig: Narkosekomplikationen (Bewegung der Gliedmaßen o. des Körpers o. Husten während der Narkose/Operation, Grimassieren o. Saugen am Endotrachealtubus), Wiederauftreten einer Blockade, Gelegentlich: Wachheit während der Narkose/Operation, Bronchospasmen bei Pat. mit pulmonalen Komplikationen in der Vorgeschichte, allergische Reakt.

Verschreibungspflichtig, **Weitere Angaben zur sicheren Anwendung d. Arzneimittels** siehe Fachinformation, **Stand d. Information: Juli 2008**. Pharmazeutischer Unternehmer: N.V. Organon, Kloosterstraat 6, 5349 AB Oss, Niederlande.

*Moderate (reappearance of second twitch [T₂]) or deep (1-2 posttetanic counts [PTCs]) neuromuscular blockade¹

**In children: routine reversal of rocuronium-induced blockade.

References: 1. BRIDION® [summary of product characteristics]. Oss, the Netherlands: N.V. Organon; 2008. 2. Bom A, Bradley M, Cameron K, et al. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by cyclodextrin-based synthetic host. *Angew Chem*. 2002;114(2):275-280.

BRIDION.com

NEW
bridion®
sugammadex

 **Essex Pharma**

Reversal just got rapid.